Clevudine

This classification denotes a reverse transcriptase inhibitor with the molecular formula C10H13FN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IN51MVP5F1, chemically known as 2,4(1h,3h)-pyrimidinedione, 1-(2-deoxy-2-fluoro-beta-l-arabinofuranosyl)-5-methyl- but generally known as clevudine, which bears US NIH Compound Identifier 73115. European Medicines Agency schedules Clevudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06656MIG. The term CLEVUDINE is an International Non-Proprietary Name. World Health Organization schedules clevudine in its Anatomical Therapeutic Chemical (ATC) Classification. CLEVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clevudine under HS 29349990 and SITC 51579. As of Q4 2014, CLEVUDINE remains the US FDA Preferred Term for this commodity. Clevudine bears US NLM identifiers UMLS ID C0045212 and NCI Concept Code C95210. SMILES: CC1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)F.